Christopher Gibson, Chief Executive Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 628,175 shares at $5.28 ($3.3M) on 2025-08-11, disclosed to the SEC on 2025-08-13.
Scheduled sale ($3.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 10,000 | $0 | 0.0% |
| 2 | $5.28 | 17,875 | $94K | 2.9% |
| 3 | $5.28 | 100,000 | $528K | 16.2% |
| 4 | $5.28 | 500,300 | $2.6M | 80.9% |
| Total | $5.20 avg | 628,175 | $3.3M | 100% |
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-04-08 | $124K | — | Filing → |